Briefly, the MRP group saw significant cardio‐metabolic improvements including weight loss (13.6 Kg), blood pressure (13 mmHg systolic), arterial stiffness, reduced concentric remodelling, insulin resistance, fasting glucose (−1.9 mmol), with 20 (83%) participants in this group achieving T2D remission by 12 weeks. The gene discussed is INS; the disease is type 2 diabetes mellitus.